SPRB SPRUCE BIOSCIENCES, INC.

CIK 0001683553 50 ready 8-Ks latest May 13, 2026, 8:05 AM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing May 26, 2026, 4:02 PM ET

Top materiality 0.90

Event mix other_material ×19 · earnings ×17 · leadership ×6

Sentiment 12 pos · 7 neg · 31 neu

Latest earnings ▼ miss 2025-Q3

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for SPRB

Highest-materiality recent filing

Spruce Biosciences discontinues tildacerfont CAH program after Phase 2b miss

December 10, 2024, 6:59 PM ET other material materiality 0.90 negative item 8.01

Phase 2b CAHmelia-204 missed primary endpoint: placebo-adjusted GC dose reduction of 0.7mg HCe (p=0.7).
98% compliance; no serious adverse events reported in CAHmelia-204.

Read filing →

May 13, 2026, 8:05 AM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Spruce Biosciences Q1 net loss $12.3M; cash $54.1M (Mar 31), $107.3M (Apr 30)

Net loss of $12.3M ($8.94 per share) for Q1 2026; R&D expenses $7.6M, G&A $4.4M.
April 22, 2026, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Spruce Biosciences prices $69M public offering of common stock and pre-funded warrants

Gross proceeds ~$69M from 1.33M shares at $50/share and 50K pre-funded warrants at $49.99.
March 20, 2026, 7:59 PM ET other material materiality 0.60 neutral item 1.02 ◈ Material Agreements

Spruce terminates Kaken collaboration for tildacerfont in Japan; reports FY 2025 results, BLA on track

Termination of Collaboration and License Agreement with Kaken effective March 31, 2026; no penalties incurred.
March 9, 2026, 7:59 PM ET earnings materiality 0.85 positive item 1.01 item 1.02 item 2.02 item 5.02 item 9.01 ◈ Material Agreements ×2◈ Earnings Releases

Spruce Biosciences reports FY2025 net loss of $39M; BLA for TA-ERT on track for Q4 2026

Net loss $39.0M for 2025 vs $53.0M in 2024; R&D expenses fell to $19.5M on cessation of CAH program.
February 5, 2026, 6:59 PM ET other material materiality 0.60 positive item 7.01 item 8.01 item 9.01

Spruce Biosciences reports long-term TA-ERT data stabilizing cognition and motor skills in MPS IIIB

TA-ERT normalized CSF HS-NRE and stabilized Bayley-III cognitive scores over up to 6 years vs decline in natural history.
January 8, 2026, 6:59 PM ET debt materiality 0.75 positive item 1.01 item 2.02 item 2.03 item 3.02 item 7.01 item 9.01 ◈ Equity Issuances ×2◈ Debt Financings◈ Material Agreements

Spruce Biosciences secures up to $50M loan facility from Avenue Capital; initial $15M funded

Loan facility up to $50M from Avenue Capital; initial $15M tranche funded on Jan 9, 2026.
November 10, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Spruce Q3 net loss $8.2M; FDA BTD for TA-ERT; $50M placement; BLA on track Q1 2026

FDA granted Breakthrough Therapy Designation for TA-ERT (MPS IIIB); BLA submission on track for Q1 2026.
October 8, 2025, 7:59 PM ET other material materiality 0.85 neutral item 1.01 item 3.02 item 8.01 item 9.01 ◈ Equity Issuances ×2

Spruce Biosciences raises $50M via stock and pre-funded warrants; BLA submission set for Q1 2026

Private placement: 502,181 shares at $68.00 and pre-funded warrants for 233,144 shares; gross proceeds ~$50M; closing expected Oct 9, 2025.
August 14, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Spruce Biosciences Q2 net loss $2.1M; TA-ERT BLA for MPS IIIB on track Q1 2026

Net loss of $2.1M for Q2 2025 vs $9.2M in Q2 2024; cash $16.4M expected to fund through end of 2025.
July 24, 2025, 7:59 PM ET other material materiality 0.70 neutral item 3.03 item 5.03 item 5.07 item 7.01 item 9.01 ◈ Governance Changes

Spruce Biosciences to effect 1-for-75 reverse stock split on Aug 4 to regain Nasdaq compliance

Reverse stock split effective 5:00 p.m. ET on August 4, 2025; shares trade split-adjusted on OTC Pink on August 5.
June 12, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 3.01 item 8.01 item 9.01

Spruce Biosciences wins Nasdaq appeal; must regain bid price compliance by Aug 5

Received Nasdaq delisting notice April 22, 2025; stock moved to OTC Pink on April 29, 2025.
May 29, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 5.03 item 3.02 item 3.03 item 5.08 item 8.01 item 9.01 ◈ Governance Changes

Spruce Biosciences issues Series A Preferred with 22M votes to Executive Chair to enable reverse stock split vote

Sold one share of Series A Preferred to Executive Chair Michael Grey for $100; shares have 22,000,000 votes on reverse stock split proposals only.
May 6, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Spruce Biosciences Q1 net loss $14.0M; cash runway to end 2025; TA-ERT BLA in 1H 2026

Q1 2025 net loss $14.0M vs $11.6M YoY; R&D includes $5.7M for SPR202 acquisition.
April 25, 2025, 7:59 PM ET other material materiality 0.85 negative item 2.05 item 3.01 item 9.01 ◈ Listing & Compliance Notices◈ Restructurings & Charges

Spruce Biosciences cuts 55% workforce; Nasdaq to delist stock on April 29

Workforce reduction of 55% approved by Board; estimated $0.9M cash charges in Q2 2025.
April 15, 2025, 7:59 PM ET other material materiality 0.85 positive item 2.02 item 9.01 item 7.01

Spruce Biosciences acquires TA-ERT for MPS IIIB; BLA submission planned 1H 2026

Acquired exclusive worldwide license for tralesinidase alfa from BioMarin for Sanfilippo Syndrome Type B, a fatal neurodegenerative disease.
December 27, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01

Spruce Biosciences CMO departing Dec 31; Kirk Ways named interim CMO

Dr. Ralph Charlton III's employment ends Dec 31, 2024; severance includes $343,200 lump sum plus 9 months COBRA.
December 10, 2024, 6:59 PM ET other material materiality 0.90 negative item 8.01

Spruce Biosciences discontinues tildacerfont CAH program after Phase 2b miss

Phase 2b CAHmelia-204 missed primary endpoint: placebo-adjusted GC dose reduction of 0.7mg HCe (p=0.7).
November 12, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Spruce Biosciences reports Q3 2024 net loss of $8.7M; cash runway through end of 2025; topline data expected Dec 2024

Net loss of $8.7M in Q3 2024 ($29.5M nine months); cash and equivalents $60.1M as of Sept 30, 2024.
October 28, 2024, 7:59 PM ET regulatory materiality 0.65 negative item 3.01

Spruce Biosciences receives Nasdaq bid-price extension to April 21, 2025; moves to Capital Market

Received Nasdaq extension until April 21, 2025 to meet $1.00 minimum bid price.
August 12, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Spruce Biosciences Q2 net loss $9.2M; cash $69.7M; MDD collaboration with HMNC

Net loss $9.2M for Q2 2024 vs $12.8M in Q2 2023; operating expenses down to $11.6M.
June 18, 2024, 7:59 PM ET M&A materiality 0.65 neutral item 1.01 item 8.01 item 9.01

Spruce Biosciences designated back-up bidder for Avexitide assets, net purchase price $34.7M

Entered stalking horse agreement June 13 for Avexitide assets; initial purchase price $10M.
June 3, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01

Spruce Biosciences Phase 2 POWER trial shows tildacerfont reduces DHEAS (p=0.020) and increases SHBG (p=0.012) in PCOS

27 women with PCOS enrolled; tildacerfont titrated to 200 mg QD vs placebo for 12 weeks.
May 13, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Spruce Biosciences Q1 net loss $11.6M; cash $81.2M; CAHmelia-204 data expected Q3 2024

Cash and cash equivalents $81.2M as of March 31, 2024; expected to fund operations through end of 2025.
April 30, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

Spruce Biosciences receives Nasdaq minimum bid price non-compliance notice

Nasdaq notified Spruce on April 26, 2024 that its stock bid price was below $1.00 for 30 consecutive business days.
March 13, 2024, 7:59 PM ET other material materiality 0.85 negative item 2.02 item 9.01 item 2.05 item 8.01 ◈ Earnings Releases◈ Restructurings & Charges

Spruce Biosciences reports CAHmelia-203 fails primary endpoint; cuts 21% workforce

CAHmelia-203 failed primary endpoint; tildacerfont 200mg QD showed -2.6% placebo-adjusted A4 reduction (non-significant).
January 8, 2024, 6:59 PM ET other material materiality 0.65 neutral item 2.02 item 9.01 item 7.01 item 8.01

Spruce Biosciences provides cash update; adult CAH trials enrollment complete; topline data expected March 2024

Cash and equivalents ~$96M as of Dec 31, 2023; 41.0M shares outstanding.
August 14, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 item 8.01 ◈ Earnings Releases

Spruce Biosciences Q2 net loss $12.8M; reports positive PCOS interim data

Net loss of $12.8M for Q2 2023 vs $11.9M for Q2 2022; six-month loss $25.6M.
May 15, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Spruce Biosciences Q1 net loss $12.8M; CAH trials near enrollment goals; PCOS study topline Q3 2023

Cash and investments $118.6M as of March 31, 2023; with Kaken $15M upfront, runway into H1 2025.
March 16, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Spruce Biosciences reports FY2022 net loss $46.2M, cash $79.1M; pipeline updates

Net loss $46.2M for FY2022 vs $42.3M in 2021; R&D expenses $35.2M, G&A $12.1M.
February 9, 2023, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 9.01 ◈ Material Agreements

Spruce Biosciences raises $53.6M in private placement of common stock and warrants

Issued 16.1M shares, 0.8M pre-funded warrants, and 12.7M standard warrants; purchase price $3.17 per share.
January 9, 2023, 6:59 PM ET other material materiality 0.80 positive item 1.01 item 2.02 item 8.01 item 9.01 ◈ Material Agreements

Spruce Biosciences licenses tildacerfont to Kaken for Japan; $15M upfront, up to $65M milestones

Exclusive Japan rights for tildacerfont in CAH; $15M upfront, up to ~$65M in development/regulatory/commercial milestones.
November 10, 2022, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Spruce Biosciences Q3 net loss $11.4M; cash $90.4M; enrollment milestones updated

Cash, cash equivalents and investments totaled $90.4M as of Sept 30, 2022.
August 10, 2022, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Spruce Biosciences reports Q2 2022 net loss of $11.9M; cash $99.1M; updates on CAH trials and leadership

Net loss of $11.9M for Q2 2022 (vs $11.8M Q2 2021); R&D spend $9.1M, flat YoY.
May 11, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Spruce Biosciences Q1 net loss $11.8M; CAHmelia-203 25% enrolled; debt facility amended

Net loss $11.8M in Q1 2022 vs $9.9M in Q1 2021; cash and investments $108.9M as of March 31, 2022.
January 5, 2022, 6:59 PM ET leadership materiality 0.75 positive item 2.02 item 8.01 item 5.02 item 9.01 ◈ executive_change ×3

Spruce Biosciences appoints Javier Szwarcberg as CEO, promotes Samir Gharib to President

Javier Szwarcberg, M.D., MPH, appointed CEO and director effective Jan 3, 2022; succeeds interim CEO Michael Grey, who remains Executive Chairman.
November 15, 2021, 6:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

Spruce Q3 net loss $11.4M; CAHmelia-203 topline delayed to 2023; CEO retired

Net loss of $11.4M for Q3 2021; cash and investments $131.3M as of Sep 30.